Phase III results for the Novel Neurokinin-1 (NK-1) Receptor Antagonist, Casopitant: Single Oral Dosing Regimen for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients (Pts) Receiving Multiple Cycles of Highly Emetogenic Chemotherapy (HEC)

Autor:	Herrstedt, Jørn, Rolski, J., Guckert, M., Camlett, I., Russo, M. W., Strausz, J., Aziz, Z.
Jazyk:	angličtina
Rok vydání:	2008
Zdroj:	Herrstedt, J, Rolski, J, Guckert, M, Camlett, I, Russo, M W, Strausz, J & Aziz, Z 2008, ' Phase III results for the Novel Neurokinin-1 (NK-1) Receptor Antagonist, Casopitant: Single Oral Dosing Regimen for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients (Pts) Receiving Multiple Cycles of Highly Emetogenic Chemotherapy (HEC) ', American Society of Clinical Oncology, Chicago, United States, 30/05/2008-03/06/2008 .
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______3062::1761323ae58b593ba13703368930e593 https://portal.findresearcher.sdu.dk/da/publications/e29380c0-a023-11dd-9b31-000ea68e967b Zobrazit plný text záznamu